Regeneron
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
CEOLeonard S. Schleifer
CEOLeonard S. Schleifer
Employees15,106
Employees15,106
HeadquartersTarrytown, New York
HeadquartersTarrytown, New York
Founded1988
Founded1988
Employees15,106
Employees15,106
REGN Key Statistics
Market cap59.08B
Market cap59.08B
Price-Earnings ratio14.28
Price-Earnings ratio14.28
Dividend yield0.16%
Dividend yield0.16%
Average volume1.58M
Average volume1.58M
High today$554.00
High today$554.00
Low today$520.50
Low today$520.50
Open price$547.88
Open price$547.88
Volume2.71M
Volume2.71M
52 Week high$1,211.20
52 Week high$1,211.20
52 Week low$520.50
52 Week low$520.50
REGN News
TipRanks 4d
Regeneron’s Promising Pipeline: Itepekimab’s Potential Impact on COPD Market and Stock RatingIn a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $958.00. Te...
Analyst ratings
73%
of 26 ratingsBuy
73.1%
Hold
19.2%
Sell
7.7%
People also own
Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.